Set­ting up a show­down with Boehringer, Pfiz­er scores in­ter­change­abil­i­ty tag for its Hu­mi­ra biosim­i­lar

Be­gin­ning lat­er this month, Pfiz­er is launch­ing an in­ter­change­able biosim­i­lar to Ab­b­Vie’s block­buster rheuma­toid arthri­tis drug Hu­mi­ra (adal­i­mum­ab) at a 5% dis­count on the whole­sale …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER